Coronary Computed Tomography Versus Invasive Angiography for Non-ST Elevation Acute Coronary Syndrome
Launched by RIGSHOSPITALET, DENMARK · Oct 20, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a non-invasive imaging test called coronary computed tomography angiography (CCTA) can be a safe and effective alternative to a more invasive procedure known as invasive coronary angiography (ICA) for diagnosing patients with certain heart conditions, specifically those experiencing non-ST-segment elevation acute coronary syndrome (NSTEACS). The goal is to see if using CCTA could lower the risks associated with the invasive procedure, make patients more comfortable, and help doctors make quicker decisions about treatment.
To participate in this trial, individuals must be admitted to the hospital with symptoms of NSTEACS and show signs of heart distress through specific tests. They should also be able to give their written consent. However, those who need immediate treatment, have certain medical histories, or have specific health conditions may not be eligible. Participants will undergo CCTA, and their experiences will help researchers understand if this approach could improve care for future patients with similar heart issues.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Admitted with non-ST-segment elevation myocardial infarction or unstable angina pectoris and an indication for subacute ICA
- • Elevated troponin or ischemic electrocardiographic changes
- • Written informed consent
- Exclusion criteria:
- • Instability requiring acute or emergent ICA
- • History of percutaneous coronary intervention or coronary artery bypass grafting
- • Estimated glomerular filtration rate \< 30 mL/min/1.73m2
- • Probable type 2 acute myocardial infarction
- • Severe valvular heart disease as primary diagnosis or potential need for valve intervention
- • History of spontaneous coronary artery dissection
- • Expected poor quality of the CCTA
- • Prior CCTA or ICA during index admission or within 1 week
- • Known allergy to beta-blockers or contrast agent
- • Pregnant or nursing
- • Previously randomized in this trial
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hvidovre, , Denmark
Copenhagen, , Denmark
Bispebjerg, , Denmark
Hillerød, , Denmark
Copenhagen, Hellerup, Denmark
Copenhagen, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported